VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q86888058 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241221010738.0
008 241221nneanz||abbn n and d
035 ‎‡a (WKP)Q86888058‏
024 ‎‡a 0000-0001-5522-5686‏ ‎‡2 orcid‏
035 ‎‡a (OCoLC)Q86888058‏
100 0 ‎‡a Daniel Gonzalez‏ ‎‡c researcher (ORCID 0000-0001-5522-5686)‏ ‎‡9 en‏
375 ‎‡a 1‏ ‎‡2 iso5218‏
400 0 ‎‡a Daniel Gonzalez‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
670 ‎‡a Author's A Dried Blood Spot Analysis for Solithromycin in Adolescents, Children, and Infants: A Short Communication‏
670 ‎‡a Author's Advances in pediatric pharmacology, therapeutics, and toxicology‏
670 ‎‡a Author's An opportunistic study evaluating pharmacokinetics of sildenafil for the treatment of pulmonary hypertension in infants.‏
670 ‎‡a Author's Assessing CYP2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition‏
670 ‎‡a Author's Association between oral sildenafil dosing, predicted exposure, and systemic hypotension in hospitalised infants.‏
670 ‎‡a Author's Can they imagine the future? A qualitative study exploring the skills employers seek in pharmaceutical sciences doctoral graduates‏
670 ‎‡a Author's Challenges and Solutions for Future Pharmacy Practice in the Era of Precision Medicine‏
670 ‎‡a Author's Clindamycin Pharmacokinetics and Safety in Preterm and Term Infants‏
670 ‎‡a Author's Clinical pharmacology considerations for children supported with ventricular assist devices‏
670 ‎‡a Author's Clinical Pharmacology Studies in Critically Ill Children.‏
670 ‎‡a Author's Dalbavancin Pharmacokinetics and Safety in Children 3 Months to 11 Years of Age.‏
670 ‎‡a Author's Development of a Pediatric Physiologically-Based Pharmacokinetic Model of Clindamycin Using Opportunistic Pharmacokinetic Data.‏
670 ‎‡a Author's Development of an Adult Physiologically Based Pharmacokinetic Model of Solithromycin in Plasma and Epithelial Lining Fluid.‏
670 ‎‡a Author's Drug Dosing and Pharmacokinetics in Children With Obesity: A Systematic Review‏
670 ‎‡a Author's Evaluation of Gentamicin Exposure in the Neonatal Intensive Care Unit and Hearing Function at Discharge‏
670 ‎‡a Author's Exposure Matching for Extrapolation of Efficacy in Pediatric Drug Development.‏
670 ‎‡a Author's Exposure Matching of Pediatric Anti-infective Drugs: Review of Drugs Submitted to the Food and Drug Administration for Pediatric Approval‏
670 ‎‡a Author's External Evaluation of a Gentamicin Infant Population Pharmacokinetic Model Using Data from a National Electronic Health Record Database‏
670 ‎‡a Author's External Evaluation of Two Fluconazole Infant Population Pharmacokinetic Models‏
670 ‎‡a Author's Fluconazole population pharmacokinetics and dosing for prevention and treatment of invasive Candidiasis in children supported with extracorporeal membrane oxygenation.‏
670 ‎‡a Author's Improving Pediatric Protein Binding Estimates: An Evaluation of α1-Acid Glycoprotein Maturation in Healthy and Infected Subjects.‏
670 ‎‡a Author's Lessons learned in pediatric clinical research to evaluate safe and effective use of drugs in pregnancy.‏
670 ‎‡a Author's Metronidazole Metabolism in Neonates and the Interplay Between Ontogeny and Genetic Variation‏
670 ‎‡a Author's Oral adherence monitoring using a breath test to supplement highly active antiretroviral therapy.‏
670 ‎‡a Author's Pediatric Drug-Drug Interaction Studies: Barriers and Opportunities‏
670 ‎‡a Author's Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.‏
670 ‎‡a Author's Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands‏
670 ‎‡a Author's Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults.‏
670 ‎‡a Author's Pharmacokinetics of Ceftaroline in a Preterm Infant With Methicillin-Resistant Staphylococcus Aureus Pneumonia.‏
670 ‎‡a Author's Pharmacokinetics of Clindamycin in Obese and Nonobese Children‏
670 ‎‡a Author's Pharmacokinetics of perioperative FVIII in adult patients with haemophilia A: An external validation and development of an alternative population pharmacokinetic model‏
670 ‎‡a Author's Pharmacologic studies in vulnerable populations: Using the pediatric experience‏
670 ‎‡a Author's Physiologically-Based Pharmacokinetic Modeling of Fluconazole Using Plasma and Cerebrospinal Fluid Samples From Preterm and Term Infants‏
670 ‎‡a Author's Population Pharmacokinetics and Exploratory Exposure-Response Relationships of Diazepam in Children Treated for Status Epilepticus‏
670 ‎‡a Author's Population Pharmacokinetics and Safety of Solithromycin following Intravenous and Oral Administration in Infants, Children, and Adolescents‏
670 ‎‡a Author's Population Pharmacokinetics of Intramuscular and Intravenous Ketamine in Children‏
670 ‎‡a Author's Population Pharmacokinetics of Milrinone in Infants, Children, and Adolescents‏
670 ‎‡a Author's Population Pharmacokinetics of Morphine in Patients With Nonalcoholic Steatohepatitis (NASH) and Healthy Adults.‏
670 ‎‡a Author's Population pharmacokinetics of sildenafil in extremely premature infants‏
670 ‎‡a Author's Population Pharmacokinetics of Trimethoprim-Sulfamethoxazole in Infants and Children.‏
670 ‎‡a Author's Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia‏
670 ‎‡a Author's Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact.‏
670 ‎‡a Author's Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage Adjustments‏
670 ‎‡a Author's Role of drug absorption in the pharmacokinetics of therapeutic interventions for stroke‏
670 ‎‡a Author's Solithromycin Pharmacokinetics in Plasma and Dried Blood Spots and Safety in Adolescents‏
670 ‎‡a Author's The Population Pharmacokinetics of High-Dose Methotrexate in Infants with Acute Lymphoblastic Leukemia Highlight the Need for Bedside Individualized Dose Adjustment: A Report from the Children's Oncology Group‏
670 ‎‡a Author's Therapeutic Drug Monitoring, Electronic Health Records, and Pharmacokinetic Modeling to Evaluate Sirolimus Drug Exposure-Response Relationships in Renal Transplant Patients‏
670 ‎‡a Author's Therapeutic Index Estimation of Antiepileptic Drugs: A Systematic Literature Review Approach.‏
670 ‎‡a Author's Thromboprophylaxis with fondaparinux in high-risk postoperative patients with renal insufficiency.‏
670 ‎‡a Author's Use of opportunistic clinical data and a population pharmacokinetic model to support dosing of clindamycin for premature infants to adolescents‏
670 ‎‡a Author's Use of Population Pharmacokinetics and Electronic Health Records to Assess Piperacillin-Tazobactam Safety in Infants‏
670 ‎‡a Author's Use of Therapeutic Drug Monitoring, Electronic Health Record Data, and Pharmacokinetic Modeling to Determine the Therapeutic Index of Phenytoin and Lamotrigine.‏
670 ‎‡a Author's Vancomycin cerebrospinal fluid pharmacokinetics in children with cerebral ventricular shunt infections.‏
670 ‎‡a Author's β2 -Adrenergic Receptor Gene Affects the Heart Rate Response of β-Blockers: Evidence From 3 Clinical Studies‏
909 ‎‡a (orcid) 0000000155225686‏ ‎‡9 1‏
919 ‎‡a roleofdrugabsorptioninthepharmacokineticsoftherapeuticinterventionsforstroke‏ ‎‡A Role of drug absorption in the pharmacokinetics of therapeutic interventions for stroke‏ ‎‡9 1‏
919 ‎‡a relevanceofliverfailureforantiinfectiveagentsfrompharmacokineticalterationstodosageadjustments‏ ‎‡A Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage Adjustments‏ ‎‡9 1‏
919 ‎‡a precisiondosingpublichealthneedproposedframeworkandanticipatedimpact‏ ‎‡A Precision Dosing: Public Health Need, Proposed Framework, and Anticipated Impact.‏ ‎‡9 1‏
919 ‎‡a populationpharmacokineticspharmacodynamicsof34diaminopyridinefreebaseinpatientswithlamberteatonmyasthenia‏ ‎‡A Population Pharmacokinetics/Pharmacodynamics of 3,4-Diaminopyridine Free Base in Patients With Lambert-Eaton Myasthenia‏ ‎‡9 1‏
919 ‎‡a populationpharmacokineticsoftrimethoprimsulfamethoxazoleininfantsandchildren‏ ‎‡A Population Pharmacokinetics of Trimethoprim-Sulfamethoxazole in Infants and Children.‏ ‎‡9 1‏
919 ‎‡a populationpharmacokineticsofsildenafilinextremelyprematureinfants‏ ‎‡A Population pharmacokinetics of sildenafil in extremely premature infants‏ ‎‡9 1‏
919 ‎‡a populationpharmacokineticsofmorphineinpatientswithnonalcoholicsteatohepatitisnashandhealthyadults‏ ‎‡A Population Pharmacokinetics of Morphine in Patients With Nonalcoholic Steatohepatitis (NASH) and Healthy Adults.‏ ‎‡9 1‏
919 ‎‡a populationpharmacokineticsofmilrinoneininfantschildrenandadolescents‏ ‎‡A Population Pharmacokinetics of Milrinone in Infants, Children, and Adolescents‏ ‎‡9 1‏
919 ‎‡a populationpharmacokineticsofintramuscularandintravenousketamineinchildren‏ ‎‡A Population Pharmacokinetics of Intramuscular and Intravenous Ketamine in Children‏ ‎‡9 1‏
919 ‎‡a populationpharmacokineticsandsafetyofsolithromycinfollowingintravenousandoraladministrationininfantschildrenandadolescents‏ ‎‡A Population Pharmacokinetics and Safety of Solithromycin following Intravenous and Oral Administration in Infants, Children, and Adolescents‏ ‎‡9 1‏
919 ‎‡a populationpharmacokineticsandexploratoryexposureresponserelationshipsofdiazepaminchildrentreatedforstatusepilepticus‏ ‎‡A Population Pharmacokinetics and Exploratory Exposure-Response Relationships of Diazepam in Children Treated for Status Epilepticus‏ ‎‡9 1‏
919 ‎‡a physiologicallybasedpharmacokineticmodelingoffluconazoleusingplasmaandcerebrospinalfluidsamplesfrompretermandterminfants‏ ‎‡A Physiologically-Based Pharmacokinetic Modeling of Fluconazole Using Plasma and Cerebrospinal Fluid Samples From Preterm and Term Infants‏ ‎‡9 1‏
919 ‎‡a pharmacologicstudiesinvulnerablepopulationsusingthepediatricexperience‏ ‎‡A Pharmacologic studies in vulnerable populations: Using the pediatric experience‏ ‎‡9 1‏
919 ‎‡a pharmacokineticsofperioperativefviiiinadultpatientswithhaemophiliaaanexternalvalidationanddevelopmentofanalternativepopulationpharmacokineticmodel‏ ‎‡A Pharmacokinetics of perioperative FVIII in adult patients with haemophilia A: An external validation and development of an alternative population pharmacokinetic model‏ ‎‡9 1‏
919 ‎‡a pharmacokineticsofclindamycininobeseandnonobesechildren‏ ‎‡A Pharmacokinetics of Clindamycin in Obese and Nonobese Children‏ ‎‡9 1‏
919 ‎‡a pharmacokineticsofceftarolineinapreterminfantwithmethicillinresistantstaphylococcusaureuspneumonia‏ ‎‡A Pharmacokinetics of Ceftaroline in a Preterm Infant With Methicillin-Resistant Staphylococcus Aureus Pneumonia.‏ ‎‡9 1‏
919 ‎‡a pharmacokineticsandsafetyofrecentlyapproveddrugsusedtotreatmethicillinresistantstaphylococcusaureusinfectionsininfantschildrenandadults‏ ‎‡A Pharmacokinetics and safety of recently approved drugs used to treat methicillin-resistant Staphylococcus aureus infections in infants, children and adults.‏ ‎‡9 1‏
919 ‎‡a pharmacokineticsanddosingoflevofloxacininchildrentreatedforactiveorlatentmultidrugresistanttuberculosisfederatedstatesofmicronesiaandrepublicofthemarshallislands‏ ‎‡A Pharmacokinetics and Dosing of Levofloxacin in Children Treated for Active or Latent Multidrug-resistant Tuberculosis, Federated States of Micronesia and Republic of the Marshall Islands‏ ‎‡9 1‏
919 ‎‡a pharmacokineticandpharmacodynamicprinciplesofantiinfectivedosing‏ ‎‡A Pharmacokinetic and Pharmacodynamic Principles of Anti-infective Dosing.‏ ‎‡9 1‏
919 ‎‡a pediatricdrugdruginteractionstudiesbarriersandopportunities‏ ‎‡A Pediatric Drug-Drug Interaction Studies: Barriers and Opportunities‏ ‎‡9 1‏
919 ‎‡a oraladherencemonitoringusingabreathtesttosupplementhighlyactiveantiretroviraltherapy‏ ‎‡A Oral adherence monitoring using a breath test to supplement highly active antiretroviral therapy.‏ ‎‡9 1‏
919 ‎‡a metronidazolemetabolisminneonatesandtheinterplaybetweenontogenyandgeneticvariation‏ ‎‡A Metronidazole Metabolism in Neonates and the Interplay Between Ontogeny and Genetic Variation‏ ‎‡9 1‏
919 ‎‡a lessonslearnedinpediatricclinicalresearchtoevaluatesafeandeffectiveuseofdrugsinpregnancy‏ ‎‡A Lessons learned in pediatric clinical research to evaluate safe and effective use of drugs in pregnancy.‏ ‎‡9 1‏
919 ‎‡a improvingpediatricproteinbindingestimatesanevaluationofα1acidglycoproteinmaturationinhealthyandinfectedsubjects‏ ‎‡A Improving Pediatric Protein Binding Estimates: An Evaluation of α1-Acid Glycoprotein Maturation in Healthy and Infected Subjects.‏ ‎‡9 1‏
919 ‎‡a fluconazolepopulationpharmacokineticsanddosingforpreventionandtreatmentofinvasivecandidiasisinchildrensupportedwithextracorporealmembraneoxygenation‏ ‎‡A Fluconazole population pharmacokinetics and dosing for prevention and treatment of invasive Candidiasis in children supported with extracorporeal membrane oxygenation.‏ ‎‡9 1‏
919 ‎‡a externalevaluationof2fluconazoleinfantpopulationpharmacokineticmodels‏ ‎‡A External Evaluation of Two Fluconazole Infant Population Pharmacokinetic Models‏ ‎‡9 1‏
919 ‎‡a externalevaluationofagentamicininfantpopulationpharmacokineticmodelusingdatafromanationalelectronichealthrecorddatabase‏ ‎‡A External Evaluation of a Gentamicin Infant Population Pharmacokinetic Model Using Data from a National Electronic Health Record Database‏ ‎‡9 1‏
919 ‎‡a exposurematchingofpediatricantiinfectivedrugsreviewofdrugssubmittedtothefoodanddrugadministrationforpediatricapproval‏ ‎‡A Exposure Matching of Pediatric Anti-infective Drugs: Review of Drugs Submitted to the Food and Drug Administration for Pediatric Approval‏ ‎‡9 1‏
919 ‎‡a exposurematchingforextrapolationofefficacyinpediatricdrugdevelopment‏ ‎‡A Exposure Matching for Extrapolation of Efficacy in Pediatric Drug Development.‏ ‎‡9 1‏
919 ‎‡a evaluationofgentamicinexposureintheneonatalintensivecareunitandhearingfunctionatdischarge‏ ‎‡A Evaluation of Gentamicin Exposure in the Neonatal Intensive Care Unit and Hearing Function at Discharge‏ ‎‡9 1‏
919 ‎‡a drugdosingandpharmacokineticsinchildrenwithobesityasystematicreview‏ ‎‡A Drug Dosing and Pharmacokinetics in Children With Obesity: A Systematic Review‏ ‎‡9 1‏
919 ‎‡a developmentofanadultphysiologicallybasedpharmacokineticmodelofsolithromycininplasmaandepithelialliningfluid‏ ‎‡A Development of an Adult Physiologically Based Pharmacokinetic Model of Solithromycin in Plasma and Epithelial Lining Fluid.‏ ‎‡9 1‏
919 ‎‡a developmentofapediatricphysiologicallybasedpharmacokineticmodelofclindamycinusingopportunisticpharmacokineticdata‏ ‎‡A Development of a Pediatric Physiologically-Based Pharmacokinetic Model of Clindamycin Using Opportunistic Pharmacokinetic Data.‏ ‎‡9 1‏
919 ‎‡a dalbavancinpharmacokineticsandsafetyinchildren3monthsto11yearsofage‏ ‎‡A Dalbavancin Pharmacokinetics and Safety in Children 3 Months to 11 Years of Age.‏ ‎‡9 1‏
919 ‎‡a clinic Alpha rmacologystudiesincriticallyillchildren‏ ‎‡A Clinical Pharmacology Studies in Critically Ill Children.‏ ‎‡9 1‏
919 ‎‡a clinic Alpha rmacologyconsiderationsforchildrensupportedwithventricularassistdevices‏ ‎‡A Clinical pharmacology considerations for children supported with ventricular assist devices‏ ‎‡9 1‏
919 ‎‡a clindamycinpharmacokineticsandsafetyinpretermandterminfants‏ ‎‡A Clindamycin Pharmacokinetics and Safety in Preterm and Term Infants‏ ‎‡9 1‏
919 ‎‡a challengesandsolutionsforfuturepharmacypracticeintheeraofprecisionmedicine‏ ‎‡A Challenges and Solutions for Future Pharmacy Practice in the Era of Precision Medicine‏ ‎‡9 1‏
919 ‎‡a cantheyimaginethefutureaqualitativestudyexploringtheskillsemployersseekinpharmaceuticalsciencesdoctoralgraduates‏ ‎‡A Can they imagine the future? A qualitative study exploring the skills employers seek in pharmaceutical sciences doctoral graduates‏ ‎‡9 1‏
919 ‎‡a associationbetweenoralsildenafildosingpredictedexposureandsystemichypotensioninhospitalisedinfants‏ ‎‡A Association between oral sildenafil dosing, predicted exposure, and systemic hypotension in hospitalised infants.‏ ‎‡9 1‏
919 ‎‡a assessingcyp2c19ontogenyinneonatesandinfantsusingphysiologicallybasedpharmacokineticmodelsimpactofenzymematurationversusinhibition‏ ‎‡A Assessing CYP2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition‏ ‎‡9 1‏
919 ‎‡a opportunisticstudyevaluatingpharmacokineticsofsildenafilforthetreatmentofpulmonaryhypertensionininfants‏ ‎‡A An opportunistic study evaluating pharmacokinetics of sildenafil for the treatment of pulmonary hypertension in infants.‏ ‎‡9 1‏
919 ‎‡a advancesinpediatricpharmacologytherapeuticsandtoxicology‏ ‎‡A Advances in pediatric pharmacology, therapeutics, and toxicology‏ ‎‡9 1‏
919 ‎‡a driedbloodspotanalysisforsolithromycininadolescentschildrenandinfantsashortcommunication‏ ‎‡A A Dried Blood Spot Analysis for Solithromycin in Adolescents, Children, and Infants: A Short Communication‏ ‎‡9 1‏
919 ‎‡a β2adrenergicreceptorgeneaffectstheheartrateresponseofβblockersevidencefrom3clinicalstudies‏ ‎‡A β2 -Adrenergic Receptor Gene Affects the Heart Rate Response of β-Blockers: Evidence From 3 Clinical Studies‏ ‎‡9 1‏
919 ‎‡a vancomycincerebrospinalfluidpharmacokineticsinchildrenwithcerebralventricularshuntinfections‏ ‎‡A Vancomycin cerebrospinal fluid pharmacokinetics in children with cerebral ventricular shunt infections.‏ ‎‡9 1‏
919 ‎‡a useoftherapeuticdrugmonitoringelectronichealthrecorddataandpharmacokineticmodelingtodeterminethetherapeuticindexofphenytoinandlamotrigine‏ ‎‡A Use of Therapeutic Drug Monitoring, Electronic Health Record Data, and Pharmacokinetic Modeling to Determine the Therapeutic Index of Phenytoin and Lamotrigine.‏ ‎‡9 1‏
919 ‎‡a useofpopulationpharmacokineticsandelectronichealthrecordstoassesspiperacillintazobactamsafetyininfants‏ ‎‡A Use of Population Pharmacokinetics and Electronic Health Records to Assess Piperacillin-Tazobactam Safety in Infants‏ ‎‡9 1‏
919 ‎‡a useofopportunisticclinicaldataandapopulationpharmacokineticmodeltosupportdosingofclindamycinforprematureinfantstoadolescents‏ ‎‡A Use of opportunistic clinical data and a population pharmacokinetic model to support dosing of clindamycin for premature infants to adolescents‏ ‎‡9 1‏
919 ‎‡a thromboprophylaxiswithfondaparinuxinhighriskpostoperativepatientswithrenalinsufficiency‏ ‎‡A Thromboprophylaxis with fondaparinux in high-risk postoperative patients with renal insufficiency.‏ ‎‡9 1‏
919 ‎‡a therapeuticindexestimationofantiepilepticdrugsasystematicliteraturereviewapproach‏ ‎‡A Therapeutic Index Estimation of Antiepileptic Drugs: A Systematic Literature Review Approach.‏ ‎‡9 1‏
919 ‎‡a therapeuticdrugmonitoringelectronichealthrecordsandpharmacokineticmodelingtoevaluatesirolimusdrugexposureresponserelationshipsinrenaltransplantpatients‏ ‎‡A Therapeutic Drug Monitoring, Electronic Health Records, and Pharmacokinetic Modeling to Evaluate Sirolimus Drug Exposure-Response Relationships in Renal Transplant Patients‏ ‎‡9 1‏
919 ‎‡a populationpharmacokineticsofhighdosemethotrexateininfantswithacutelymphoblasticleukemiahighlighttheneedforbedsideindividualizeddoseadjustmentareportfromthechildrensoncologygroup‏ ‎‡A The Population Pharmacokinetics of High-Dose Methotrexate in Infants with Acute Lymphoblastic Leukemia Highlight the Need for Bedside Individualized Dose Adjustment: A Report from the Children's Oncology Group‏ ‎‡9 1‏
919 ‎‡a solithromycinpharmacokineticsinplasmaanddriedbloodspotsandsafetyinadolescents‏ ‎‡A Solithromycin Pharmacokinetics in Plasma and Dried Blood Spots and Safety in Adolescents‏ ‎‡9 1‏
946 ‎‡a b‏ ‎‡9 1‏
996 ‎‡2 BNE|XX1026470‏
996 ‎‡2 SUDOC|184311845‏
996 ‎‡2 ISNI|0000000081321164‏
996 ‎‡2 RERO|A012771478‏
996 ‎‡2 LC|ns2017001144‏
996 ‎‡2 BNE|XX1004208‏
996 ‎‡2 BNCHL|10000000000000000268511‏
996 ‎‡2 BNCHL|10000000000000000809270‏
996 ‎‡2 PTBNP|1800554‏
996 ‎‡2 ISNI|0000000029399845‏
996 ‎‡2 BNE|XX5418835‏
996 ‎‡2 ISNI|0000000059884358‏
996 ‎‡2 NKC|jo2015888225‏
996 ‎‡2 BNE|XX1140644‏
996 ‎‡2 DNB|1057177261‏
996 ‎‡2 BNCHL|10000000000000000143292‏
996 ‎‡2 BNE|XX5790394‏
996 ‎‡2 BNC|981058613196106706‏
996 ‎‡2 ARBABN|000061097‏
996 ‎‡2 SUDOC|263075079‏
996 ‎‡2 DNB|1336133872‏
996 ‎‡2 LNB|LNC10-000276161‏
996 ‎‡2 LC|no2022074508‏
996 ‎‡2 LC|no2014160212‏
996 ‎‡2 LC|no2009198052‏
996 ‎‡2 BNE|XX6136614‏
996 ‎‡2 NTA|315896388‏
996 ‎‡2 ISNI|0000000036747473‏
996 ‎‡2 LC|no2011022251‏
996 ‎‡2 DNB|1057379123‏
996 ‎‡2 BNE|XX1050171‏
996 ‎‡2 BNE|XX5152569‏
996 ‎‡2 LC|no2022090068‏
996 ‎‡2 DNB|1124403701‏
996 ‎‡2 BNC|981058508623206706‏
996 ‎‡2 SUDOC|189788968‏
996 ‎‡2 DNB|135486238‏
996 ‎‡2 ISNI|0000000051295495‏
996 ‎‡2 BNC|981061005071506706‏
996 ‎‡2 LC|no2023025438‏
996 ‎‡2 SUDOC|244422192‏
996 ‎‡2 SUDOC|183440161‏
996 ‎‡2 ISNI|0000000024288628‏
996 ‎‡2 LC|ns2024002313‏
996 ‎‡2 BNE|XX5263823‏
996 ‎‡2 LC|no2010079980‏
996 ‎‡2 ISNI|0000000391273866‏
996 ‎‡2 LC|nr2003018103‏
996 ‎‡2 BNE|XX1666800‏
996 ‎‡2 J9U|987007344428705171‏
996 ‎‡2 LC|no2010025984‏
996 ‎‡2 BNE|XX1099566‏
996 ‎‡2 LC|no2018110765‏
996 ‎‡2 LC|no2024137563‏
996 ‎‡2 LC|n 2022053373‏
996 ‎‡2 ISNI|0000000497587521‏
996 ‎‡2 SUDOC|238484548‏
996 ‎‡2 DNB|1262404282‏
996 ‎‡2 DNB|1056378506‏
996 ‎‡2 DNB|1018632166‏
996 ‎‡2 BNCHL|10000000000000000178121‏
996 ‎‡2 ISNI|000000005459620X‏
996 ‎‡2 BIBSYS|6017860‏
996 ‎‡2 BNE|XX1690276‏
996 ‎‡2 BNC|981058515685206706‏
996 ‎‡2 LC|n 2022049146‏
996 ‎‡2 BNC|981058525722306706‏
996 ‎‡2 BNE|XX5475333‏
996 ‎‡2 LC|no2009154963‏
996 ‎‡2 LC|n 90687592‏
996 ‎‡2 LC|n 93016727‏
996 ‎‡2 DNB|131993585‏
996 ‎‡2 BNE|XX5845721‏
996 ‎‡2 LC|n 2014036531‏
996 ‎‡2 LC|n 00109964‏
996 ‎‡2 SUDOC|203006267‏
996 ‎‡2 PTBNP|1608360‏
996 ‎‡2 BNE|XX1481964‏
996 ‎‡2 PTBNP|1590363‏
996 ‎‡2 ISNI|0000000060864012‏
996 ‎‡2 LC|n 78047672‏
996 ‎‡2 BNE|XX4941341‏
996 ‎‡2 ISNI|0000000023598536‏
996 ‎‡2 LC|no2008031220‏
996 ‎‡2 BNE|XX954803‏
996 ‎‡2 BNE|XX1535672‏
996 ‎‡2 BNC|981060730472906706‏
996 ‎‡2 LC|n 2003097823‏
996 ‎‡2 LC|nr 91033287‏
996 ‎‡2 BNC|981060022460506706‏
996 ‎‡2 BNE|XX1504691‏
996 ‎‡2 ISNI|0000000043662013‏
996 ‎‡2 RERO|A011034737‏
996 ‎‡2 BIBSYS|99002178‏
996 ‎‡2 DNB|114119256X‏
996 ‎‡2 ISNI|0000000049714486‏
996 ‎‡2 DNB|1241588163‏
996 ‎‡2 BNCHL|10000000000000000865046‏
996 ‎‡2 ISNI|0000000034036854‏
996 ‎‡2 LC|no2013012066‏
996 ‎‡2 BNE|XX5693230‏
996 ‎‡2 LC|nr2001036995‏
996 ‎‡2 SUDOC|254859003‏
996 ‎‡2 SUDOC|178309109‏
996 ‎‡2 DBC|87097990828037‏
996 ‎‡2 LC|n 2011049753‏
996 ‎‡2 LC|n 2014064462‏
996 ‎‡2 BNE|XX1587189‏
996 ‎‡2 ISNI|0000000077239774‏
996 ‎‡2 BNC|981061127957306706‏
996 ‎‡2 BNE|XX1629355‏
996 ‎‡2 ISNI|0000000118459213‏
996 ‎‡2 BNE|XX5015638‏
996 ‎‡2 BNE|XX4686641‏
996 ‎‡2 BNE|XX1046717‏
996 ‎‡2 BNC|981058517357306706‏
996 ‎‡2 LC|no2009103620‏
996 ‎‡2 LC|n 2004027453‏
996 ‎‡2 RERO|A014085938‏
996 ‎‡2 BNE|XX938263‏
996 ‎‡2 ARBABN|000069127‏
996 ‎‡2 BNC|981058614486006706‏
996 ‎‡2 BNE|XX1045053‏
996 ‎‡2 LC|no2016172205‏
996 ‎‡2 DNB|1089593104‏
996 ‎‡2 BNC|981058608318206706‏
996 ‎‡2 NYNYRILM|222992‏
996 ‎‡2 SUDOC|268452881‏
996 ‎‡2 BNE|XX6306505‏
996 ‎‡2 DNB|138387370‏
996 ‎‡2 LC|no2014155837‏
996 ‎‡2 J9U|987012500607005171‏
996 ‎‡2 BNC|981058610445606706‏
996 ‎‡2 BNE|XX819266‏
996 ‎‡2 BNE|XX1534118‏
996 ‎‡2 SKMASNL|vtls010785282‏
996 ‎‡2 NUKAT|n 2019062849‏
996 ‎‡2 DNB|1056471425‏
996 ‎‡2 SUDOC|243671369‏
996 ‎‡2 LC|no2005107928‏
996 ‎‡2 BNF|14575235‏
996 ‎‡2 CAOONL|ncf11403392‏
996 ‎‡2 SUDOC|166516406‏
996 ‎‡2 SUDOC|195244915‏
996 ‎‡2 SUDOC|237785331‏
996 ‎‡2 BIBSYS|12032736‏
996 ‎‡2 DNB|105639580X‏
996 ‎‡2 DNB|1057138460‏
996 ‎‡2 ISNI|0000000077041741‏
996 ‎‡2 BNC|981058511977106706‏
996 ‎‡2 RERO|A024801729‏
996 ‎‡2 NTA|333294432‏
996 ‎‡2 BNCHL|10000000000000000288231‏
996 ‎‡2 LC|n 2022013025‏
996 ‎‡2 SUDOC|277425891‏
996 ‎‡2 PLWABN|9813174229105606‏
996 ‎‡2 BNE|XX5794086‏
996 ‎‡2 ISNI|000000012146761X‏
996 ‎‡2 ISNI|0000000485165890‏
996 ‎‡2 ISNI|0000000073368472‏
996 ‎‡2 BNC|981060546115406706‏
996 ‎‡2 BNE|XX4435682‏
996 ‎‡2 DNB|1056340754‏
996 ‎‡2 BNE|XX922911‏
996 ‎‡2 DNB|1236995112‏
996 ‎‡2 ISNI|0000000121465139‏
996 ‎‡2 BNCHL|10000000000000000820412‏
996 ‎‡2 SUDOC|120194317‏
996 ‎‡2 ARBABN|000022081‏
996 ‎‡2 BNC|981058594887206706‏
996 ‎‡2 BIBSYS|2071166‏
996 ‎‡2 ISNI|0000000116724300‏
996 ‎‡2 BNC|981058510892306706‏
996 ‎‡2 ISNI|0000000436976523‏
996 ‎‡2 JPG|500643647‏
996 ‎‡2 ISNI|0000000032206880‏
996 ‎‡2 PLWABN|9811714800705606‏
996 ‎‡2 ISNI|0000000061109756‏
996 ‎‡2 ISNI|000000005501702X‏
996 ‎‡2 BNF|16556990‏
996 ‎‡2 RERO|A003307569‏
996 ‎‡2 NKC|pna2017951128‏
996 ‎‡2 BNE|XX1110333‏
996 ‎‡2 BNE|XX4865475‏
996 ‎‡2 SUDOC|230096085‏
996 ‎‡2 J9U|987007319311105171‏
996 ‎‡2 BNE|XX1195344‏
996 ‎‡2 ISNI|0000000059377655‏
996 ‎‡2 LC|no2017167230‏
996 ‎‡2 PLWABN|9811986253005606‏
996 ‎‡2 NDL|001315703‏
996 ‎‡2 BNE|XX4873990‏
996 ‎‡2 LC|ns2024001857‏
996 ‎‡2 DNB|1197077758‏
996 ‎‡2 LC|no2023120723‏
996 ‎‡2 LC|n 2010059315‏
996 ‎‡2 ISNI|0000000118505427‏
996 ‎‡2 CAOONL|ncf10486843‏
996 ‎‡2 DNB|1237024838‏
996 ‎‡2 BNF|13531695‏
996 ‎‡2 NSK|000705260‏
996 ‎‡2 SZ|1241588163‏
996 ‎‡2 SUDOC|134494563‏
996 ‎‡2 LC|no2014035346‏
996 ‎‡2 J9U|987007524250705171‏
996 ‎‡2 ISNI|0000000121027972‏
996 ‎‡2 SUDOC|155366688‏
996 ‎‡2 LC|no2010091984‏
996 ‎‡2 LC|no2024080307‏
996 ‎‡2 SUDOC|257914625‏
996 ‎‡2 BNE|XX1588628‏
996 ‎‡2 BNE|XX4722904‏
996 ‎‡2 LC|no2005094672‏
996 ‎‡2 LC|no2023088465‏
996 ‎‡2 ISNI|0000000504143006‏
996 ‎‡2 BNC|981058611882006706‏
996 ‎‡2 SUDOC|139884734‏
996 ‎‡2 ARBABN|000070699‏
996 ‎‡2 BNC|981058610727206706‏
996 ‎‡2 SZ|1048255921‏
996 ‎‡2 BNE|XX1260540‏
996 ‎‡2 BNE|XX6522877‏
996 ‎‡2 ISNI|0000000493898066‏
996 ‎‡2 SUDOC|138897913‏
996 ‎‡2 SUDOC|26770626X‏
996 ‎‡2 BNE|XX1124651‏
996 ‎‡2 BNC|981058516653506706‏
996 ‎‡2 LC|no2018058671‏
996 ‎‡2 BNCHL|10000000000000000832925‏
996 ‎‡2 ISNI|0000000382254209‏
996 ‎‡2 NTA|297609092‏
996 ‎‡2 BNE|XX5595526‏
996 ‎‡2 BNCHL|10000000000000000010355‏
996 ‎‡2 BNE|XX1780606‏
996 ‎‡2 BNCHL|10000000000000000275862‏
996 ‎‡2 LC|no2003094354‏
996 ‎‡2 BNCHL|10000000000000000030226‏
996 ‎‡2 SUDOC|151319693‏
996 ‎‡2 SUDOC|094642346‏
996 ‎‡2 BNE|XX4448144‏
996 ‎‡2 LC|n 2002092072‏
996 ‎‡2 BNE|XX6038486‏
996 ‎‡2 NDL|01020100‏
996 ‎‡2 ISNI|000000003277532X‏
996 ‎‡2 RERO|A003307660‏
996 ‎‡2 ISNI|0000000072109129‏
996 ‎‡2 ARBABN|000071501‏
996 ‎‡2 BNC|981058520347106706‏
996 ‎‡2 ISNI|0000000047452275‏
996 ‎‡2 ISNI|0000000075406153‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏